Using autochthonous mouse models of aggressive lymphoma to systematically distill actionable vulnerabilities

This project focuses on cluster 5 DLBCL, for which a large collection of genetically engineered mice has been established. The project will expand on these efforts, to develop comprehensive and versatile in vivo preclinical platforms that employ a combination of large-scale in vitro vulnerability screening, and an in vivo validation tool box, to develop innovative and genomics-guided approaches for the treatment of genetically-defined high-risk DLBCL patients. We will also perform an in vivo CRISPR/Cas9 screen in CAR-T cells, to search for T cell-specific genes and pathways which propel the anti-lymphoma CAR-T cell response.


Prof. Dr. med. Hans Christian Reinhardt

Department of Hematology and Stem Cell Transplantation

University Hospital Essen

Hufelandstraße 55

45147 Essen